All Pharma News
Teva weighs potential sale of its $2B API business

Teva weighs potential sale of its $2B API business
Fraiser Kansteiner FIERCE PHARMA
07 Jul 2023
Share Share
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
PRESS RELEASE
06 Jan 2023
Share Share
Teva, Allergan poised to put their opioid lawsuits to bed

Teva, Allergan poised to put their opioid lawsuits to bed
Fraiser Kansteiner FIERCEPHARMA
23 Nov 2022
Share Share
Teva Finalizes Nationwide Opioid Settlement Terms

Teva Finalizes Nationwide Opioid Settlement Terms
BUSINESSWIRE
22 Nov 2022
Share Share
Teva Pharma Appoints Novartis, Biogen Vet as New President and CEO

Teva Pharma Appoints Novartis, Biogen Vet as New President and CEO
Mark Terry BIOSPACE
22 Nov 2022
Share Share
Teva Announces Collabo with Rimidi to Expand Reach Respiratory Digital Health

Teva Announces Collabo with Rimidi to Expand Reach Respiratory Digital Health
BUSINESSWIRE
14 Nov 2022
Share Share
Teva Announces Unique Collab with HealthSnap of its Respiratory Digital Health

Teva Announces Unique Collab with HealthSnap of its Respiratory Digital Health
TEVAPHARM
14 Nov 2022
Share Share
Teva`s Generic Penciclovir Receives Approval in the U.S.

Teva`s Generic Penciclovir Receives Approval in the U.S.
FDA
09 Nov 2022
Share Share
Teva refiles long-acting schizophrenia drug after FDA rejection

Teva refiles long-acting schizophrenia drug after FDA rejection
Nick Paul Taylor FIERCEPHARMA
08 Nov 2022
Share Share
Teva to Present Research from CONNECT1 and CONNECT2 Trials at ACAAI

Teva to Present Research from CONNECT1 and CONNECT2 Trials at ACAAI
BUSINESSWIRE
07 Nov 2022
Share Share